Belumosudil is an oral medication approved by the FDA in 2021 for treating chronic graft-versus-host disease (cGvHD) in patients who have not responded to prior therapies. It works by inhibiting ROCK2, a protein involved in immune regulation and fibrosis, helping to reduce inflammation and tissue damage. Unlike traditional antibiotics, belumosudil targets immune pathways rather than bacteria, offering a specialized approach for managing difficult-to-treat immune conditions.
BRAND NAMES
Belumosudil (Rezurock) is an FDA-approved oral drug for chronic graft-versus-host disease. It inhibits ROCK2 to reduce immune-related inflammation and fibrosis, offering targeted therapy for patients unresponsive to other treatments.
MECHANISM OF ACTION
Belumosudil works by selectively inhibiting Rho-associated coiled-coil kinase 2 (ROCK2). This enzyme regulates immune cell signaling and the production of fibrotic proteins. By blocking ROCK2, belumosudil reduces the activity of pro-inflammatory and pro-fibrotic pathways, helping to control immune-mediated tissue damage and fibrosis in conditions like chronic graft-versus-host disease.
PHARMACOKINETICS
Absorption
Belumosudil is well absorbed orally, with peak plasma concentrations typically reached 1 to4 hours after ingestion. Food may slightly affect its absorption, but it can generally be taken with or without meals. Its oral bioavailability allows consistent systemic exposure, which is important for its effectiveness in treating chronic graft-versus-host disease.
Distribution
Belumosudil is widely distributed throughout the body after oral absorption. It binds moderately to plasma proteins and can reach various tissues, allowing it to effectively target immune and fibrotic pathways involved in chronic graft-versus-host disease.
Metabolism
Belumosudil is primarily metabolized in the liver, mainly by the CYP3A4 enzyme. This metabolism converts the drug into inactive metabolites, which are then prepared for elimination from the body.
Excretion
Belumosudil is mainly excreted through feces, with a smaller portion eliminated in the urine. Most of the drug is removed from the body as metabolites rather than unchanged drug, reflecting its liver metabolism.
PHARMACODYNAMICS
Belumosudil works by selectively inhibiting ROCK2, reducing inflammation and fibrosis. This modulation of immune pathways helps prevent tissue damage and control symptoms in chronic graft-versus-host disease.
ADMINISTRATION
Belumosudil is administered orally as tablets, usually taken oncedaily with or without food, following the dosage prescribed by a healthcare provider for chronic graft-versus-host disease.
DOSAGE AND STRENGTH
Belumosudil (Rezurock) is typically available in 200 mg oral tablets. The usual recommended dosage for adults with chronic graft-versus-host disease is 200 mg once daily, taken with or without food, as directed by a healthcare provider.
FOOD INTERACTIONS
Belumosudil can be taken with or without food, as food has minimal effect on its absorption. However, high-fat meals may slightly delay peak blood levels but do not significantly affect overall drug exposure.
DRUG INTERACTIONS
CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) can increase belumosudil levels, raising the risk of side effects.
CYP3A4 inducers (e.g., rifampin, carbamazepine) can decrease its levels, reducing effectiveness.
Concomitant use with strong P-glycoprotein (P-gp) modulators may also alter absorption.
CONTRAINDICATIONS
Known hypersensitivity to belumosudil or any component of the tablet.
Severe liver impairment (as metabolism is primarily hepatic) without careful medical supervision.
SIDE EFFECTS
Common side effects of belumosudil include:
Fatigue
Nausea
Diarrhea
Shortness of breath (dyspnea)
Cough
Swelling (edema)
Headache
TOXICITY
Belumosudil toxicity can occur from high doses or drug interactions, leading to liver enzyme elevation, increased infection risk, gastrointestinal upset, and fatigue. Management includes dose adjustment, supportive care, and close monitoring.
